AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

AstraZeneca has agreed to acquire Belgian ... in quick succession by a pair of licensing deals with South Korea's Alteogen for a hyaluronidase technology (ALT-B4) that can be used to create ...

FDA finds benzene contamination, Tronox to close a pigment plant, Sofinnova launches a European biotech fund, and more ...

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease ...

In March, AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs as well as a deal to buy EsoBiotech for up to $1 billion. From a clinical perspective, ...

With the new $94 million (€90 million) funding, the company will develop its pipeline of oral macrocycle drugs, nCycles, against validated biologic targets.